Literature DB >> 8107459

Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol, and diazepam.

T H Kelly1, R W Foltin, C S Emurian, M W Fischman.   

Abstract

The time courses of the effects of acute doses of amphetamine (5 and 10 mg/70 kg), alcohol (0.3 and 0.6 g/kg), diazepam (5 and 10 mg/70 kg), and marijuana (2.0% and 3.5% delta 9-THC) on performance engendered by each of four computerized behavioral tasks were evaluated in six human subjects. These performance-based tasks have potential commercial utility for drug-use detection in the workplace. Alcohol and marijuana effects were reliably detected for up to three hours following dose administration with most procedures. Amphetamine and diazepam effects were also detected, but the dose effects and time courses were variable. The profile of behavioral effects varied across drugs, suggesting that performance-based testing procedures might be useful in discriminating which drug was administered and the time course of the drug's effects. Results indicate that repeated measurement with performance-based drug detection procedures can provide immediate indications of performance impairment in a cost-effective and noninvasive manner and, as such, would be a useful supplement to biological sample testing for drug-use detection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8107459     DOI: 10.1093/jat/17.5.264

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  30 in total

1.  Pupillometry is not sensitive to gas narcosis in divers breathing hyperbaric air or normobaric nitrous oxide.

Authors:  Xavier Ce Vrijdag; Hanna van Waart; Jamie W Sleigh; Simon J Mitchell
Journal:  Diving Hyperb Med       Date:  2020-06-30       Impact factor: 0.887

2.  Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

Authors:  Maria A Sullivan; Suzanne K Vosburg; Sandra D Comer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-14       Impact factor: 4.530

3.  Amphetamine self-administration by humans: modulation by contingencies associated with task performance.

Authors:  S D Comer; M Haney; R W Foltin; M W Fischman
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

4.  Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Drug Alcohol Depend       Date:  2011-01-11       Impact factor: 4.492

5.  Depot naltrexone: long-lasting antagonism of the effects of heroin in humans.

Authors:  Sandra D Comer; Eric D Collins; Herbert D Kleber; Elie S Nuwayser; James H Kerrigan; Marian W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-11-01       Impact factor: 4.530

6.  Smoked marijuana attenuates performance and mood disruptions during simulated night shift work.

Authors:  Diana R Keith; Erik W Gunderson; Margaret Haney; Richard W Foltin; Carl L Hart
Journal:  Drug Alcohol Depend       Date:  2017-06-28       Impact factor: 4.492

Review 7.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Methamphetamine attenuates disruptions in performance and mood during simulated night-shift work.

Authors:  Carl L Hart; Amie S Ward; Margaret Haney; Jennifer Nasser; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2003-05-07       Impact factor: 4.530

9.  Methamphetamine self-administration by humans subjected to abrupt shift and sleep schedule changes.

Authors:  Matthew G Kirkpatrick; Margaret Haney; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin; Carl L Hart
Journal:  Psychopharmacology (Berl)       Date:  2008-12-04       Impact factor: 4.530

10.  Acute d-amphetamine pretreatment does not alter stimulant self-administration in humans.

Authors:  William W Stoops; Andrea R Vansickel; Joshua A Lile; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2007-04-05       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.